ArticleESMO open2026
Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRibociclib remains the only cyclin-dependent kinase 4/6 inhibitor to consistently demonstrate overall survival (OS) benefits in the metastatic breast cancer (MBC) setting, with statistically significant and clinically meaningful OS results from all three MONALEESA studies in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER)-negative MBC. However, real-world (RW) data concerning ribociclib are limited, with brief follow-up durations among RW patients restricting comprehensive OS assessments. Hence, real-world progression-free survival 2 (rwPFS2) and real-world chemotherapy-free survival (rwCFS) can serve as reliable postprogression endpoints. MATERIALS AND
methodsThis retrospective analysis utilized deidentified electronic health record data from the Flatiron Health Research Database, evaluating female patients with HR-positive/HER2-negative MBC who initiated first-line treatment with ribociclib plus an aromatase inhibitor (AI) (n = 2571) or AI monotherapy (n = 3078) between 1 January 2020 and 31 January 2025. Analyses were adjusted using inverse probability of treatment weighting.
resultsIn the overall cohort, risk of rwPFS2 event was 42% lower with ribociclib plus AI versus AI monotherapy [hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.52-0.65]. A consistent 42% reduction in risk of rwPFS2 event was also observed among patients aged ≥65 years (HR 0.58, 95% CI 0.49-0.68). Risk of rwCFS event was 36% lower with ribociclib plus AI versus AI alone in the overall cohort (HR 0.64, 95% CI 0.57-0.72) and 40% lower among patients aged ≥65 years (HR 0.60, 95% CI 0.51-0.71).
conclusionsThese RW findings align with clinical trial results, reinforcing that ribociclib provides consistent and substantial postprogression survival benefit for patients with HR-positive/HER2-negative MBC, including those aged ≥65 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.